RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01251172 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Lack of Drug Supply

Conditions

DS Stage I Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation
DRUG: Gamma-Secretase Inhibitor RO4929097
PROCEDURE: Hematopoietic Stem Cell Mobilization
PROCEDURE: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
OTHER: Laboratory Biomarker Analysis
DRUG: Melphalan

Sponsor

National Cancer Institute (NCI)